Telix Pharma报告说,2025年的Q3收入增长强劲,美国和欧洲的核准扩大,并进行了先进的多重癌症试验。 Telix Pharma reported strong Q3 2025 revenue growth, expanded U.S. and European approvals, and advanced multiple cancer trials.

Telix制药公司报告,未经审计的2025年Q3收入为2.06亿美元,比上一年增加53%,并将2025年全年收入预测提高到8亿至8.2亿美元。 Telix Pharmaceuticals reported $206 million in unaudited Q3 2025 revenue, a 53% year-over-year increase, and raised its full-year 2025 revenue forecast to $800–820 million. Gozellix 从 2025 年 10 月 1 日开始通过 II 级 HCPCS 代码和过渡性直通付款实现了美国全额报销。 Gozellix achieved full U.S. reimbursement starting October 1, 2025, with a Level II HCPCS code and Transitional Pass-Through payment. Illuccix在19个欧洲市场和联合王国获得了批准,在几个国家进行了商业发射。 Illuccix received approval in 19 European markets and the UK, with commercial launches in several countries. Telix与PSMA-PET一起启动了BiPASS第3阶段的MRI试验测试,用于前列腺癌诊断,并将TLX591在ProstACT第3阶段试验的入学人数扩大到多个国家。 Telix initiated the BiPASS Phase 3 trial testing MRI with PSMA-PET for prostate cancer diagnosis and expanded enrollment in the ProstACT Phase 3 trial for TLX591 to multiple countries. 目前正在对TLX250,TLX101,TLX400和其他候选药物进行额外的试验,在肉瘤中对TLX400报告有希望的结果. Additional trials are underway for TLX250, TLX101, TLX400, and other candidates, with promising results reported for TLX400 in sarcoma. Telix仍然是美国唯一一家拥有两个经林业发展局批准的PSMA成像剂的公司。 Telix remains the only company with two FDA-approved PSMA imaging agents in the U.S.